A weighted method for estimation of receptor occupancy for pharmacodynamic measurements in drug development

被引:7
作者
Sternebring, Ola [1 ]
Alifrangis, Lene [1 ]
Christensen, Toke Folke [2 ]
Ji, Hong [3 ]
Hegelund, Anne Charlotte [4 ]
Hogerkorp, Carl-Magnus [3 ]
机构
[1] Novo Nordisk AS, Dept Dev DMPK, DK-2760 Malov, Denmark
[2] Novo Nordisk AS, Dept Quantitat Clin Pharmacol, DK-2860 Soborg, Denmark
[3] Novo Nordisk AS, Dept Pharmacodynam, Novo Nordisk Pk, DK-2760 Malov, Denmark
[4] Novo Nordisk AS, Dept Dev Bioanal, DK-2760 Malov, Denmark
关键词
receptor occupancy; pharmacodynamics; flow cytometry; biomarker; clinical trial; drug development; RESEARCH-AND-DEVELOPMENT; MONOCLONAL-ANTIBODY; PHASE-I; RHEUMATOID-ARTHRITIS; CLINICAL ACTIVITY; HEALTHY-SUBJECTS; DOUBLE-BLIND; SAFETY; PHARMACOKINETICS; TRIAL;
D O I
10.1002/cyto.b.21277
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
BackgroundFlow cytometry-based receptor occupancy (RO) assessments for pharmacodynamic (PD) response measurements along with drug pharmacokinetic (PK) measurements represent a cornerstone in mechanism based PK/PD modeling of drugs against cell surface targets. This report describes the utility of using a Free and a Bound assay in combination to derive RO estimations through a weighted calculation method. MethodsData from a RO assay validation study in human samples was used to explore the performance of various RO data calculation methods. The calculation methods were subsequently applied to investigate the best method to generate RO data in a first in human phase 1 clinical trial. Finally, the outcome of the analysis was used for PK/PD modeling of a prospective phase 2a trial. ResultsThe validation data assessment demonstrated that a weighted RO calculation method had a better performance in terms of precision, accuracy and dynamic range. In the phase 1 clinical trial data analysis the weighted method again demonstrated a better performance resulting in a more robust RO estimation, and subsequently also generating a more reliable PK/PD simulation for the phase 2a trial. ConclusionsThis report demonstrated the utility of using a combined Free and Bound RO assessment together with a weighted calculation method to better support mechanism-based PK/PD modeling activities. (c) 2015 International Clinical Cytometry Society
引用
收藏
页码:220 / 229
页数:10
相关论文
共 36 条
[1]   Safety, Pharmacokinetics, and Preliminary Clinical Activity of Inotuzumab Ozogamicin, a Novel Immunoconjugate for the Treatment of B-Cell Non-Hodgkin's Lymphoma: Results of a Phase I Study [J].
Advani, Anjali ;
Coiffier, Bertrand ;
Czuczman, Myron S. ;
Dreyling, Martin ;
Foran, James ;
Gine, Eva ;
Gisselbrecht, Christian ;
Ketterer, Nicolas ;
Nasta, Sunita ;
Rohatiner, Ama ;
Schmidt-Wolf, Ingo G. H. ;
Schuler, Martin ;
Sierra, Jorge ;
Smith, Mitchell R. ;
Verhoef, Gregor ;
Winter, Jane N. ;
Boni, Joseph ;
Vandendries, Erik ;
Shapiro, Mark ;
Fayad, Luis .
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (12) :2085-2093
[2]   A phase 1 study of lucatumumab, a fully human anti-CD40 antagonist monoclonal antibody administered intravenously to patients with relapsed or refractory multiple myeloma [J].
Bensinger, William ;
Maziarz, Richard T. ;
Jagannath, Sundar ;
Spencer, Andrew ;
Durrant, Simon ;
Becker, Pamela S. ;
Ewald, Brett ;
Bilic, Sanela ;
Rediske, John ;
Baeck, Johan ;
Stadtmauer, Edward A. .
BRITISH JOURNAL OF HAEMATOLOGY, 2012, 159 (01) :58-66
[3]   Phase I Study of Single-Agent Anti-Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates [J].
Brahmer, Julie R. ;
Drake, Charles G. ;
Wollner, Ira ;
Powderly, John D. ;
Picus, Joel ;
Sharfman, William H. ;
Stankevich, Elizabeth ;
Pons, Alice ;
Salay, Theresa M. ;
McMiller, Tracee L. ;
Gilson, Marta M. ;
Wang, Changyu ;
Selby, Mark ;
Taube, Janis M. ;
Anders, Robert ;
Chen, Lieping ;
Korman, Alan J. ;
Pardoll, Drew M. ;
Lowy, Israel ;
Topalian, Suzanne L. .
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (19) :3167-3175
[4]   Phase I study of the anti-CD40 humanized monoclonal antibody lucatumumab (HCD122) in relapsed chronic lymphocytic leukemia [J].
Byrd, John C. ;
Kipps, Thomas J. ;
Flinn, Ian W. ;
Cooper, Maureen ;
Odenike, Olatoyosi ;
Bendiske, Jennifer ;
Rediske, John ;
Bilic, Sanela ;
Dey, Jyotirmoy ;
Baeck, Johan ;
O'Brien, Susan .
LEUKEMIA & LYMPHOMA, 2012, 53 (11) :2136-2142
[5]   A chromatic explosion: the development and future of multiparameter flow cytometry [J].
Chattopadhyay, Pratip K. ;
Hogerkorp, Carl-Magnus ;
Roederer, Mario .
IMMUNOLOGY, 2008, 125 (04) :441-449
[6]   Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework [J].
Cook, David ;
Brown, Dearg ;
Alexander, Robert ;
March, Ruth ;
Morgan, Paul ;
Satterthwaite, Gemma ;
Pangalos, Menelas N. .
NATURE REVIEWS DRUG DISCOVERY, 2014, 13 (06) :419-431
[7]   In vitro and clinical investigation of the relationship between CCR5 receptor occupancy and Anti-HIV activity of aplaviroc [J].
Demarest, James F. ;
Sparks, Sara S. ;
Schell, Kathleen ;
Shibayama, Shiro ;
McDanal, Charlene B. ;
Fang, Lei ;
Adkison, Kimberly K. ;
Shachoy-Clark, Anne ;
Piscitelli, Stephen C. .
JOURNAL OF CLINICAL PHARMACOLOGY, 2008, 48 (10) :1179-1188
[8]  
Derendorf H, 2000, J CLIN PHARMACOL, V40, P1399
[9]   Modeling of pharmacokinetic/pharmacodynamic (PK/PD) relationships: Concepts and perspectives [J].
Derendorf, H ;
Meibohm, B .
PHARMACEUTICAL RESEARCH, 1999, 16 (02) :176-185
[10]   Precision medicine: an approach to R&D for delivering superior medicines to patients [J].
Dolsten, Mikael ;
Sogaard, Morten .
CLINICAL AND TRANSLATIONAL MEDICINE, 2012, 1